Bristol-Myers Bulks Up Cancer Portfolio With $74 Bln Celgene Deal Bristol-Myers Bulks Up Cancer Portfolio With $74 Bln Celgene Deal

Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, creating a major pharma company with several blockbuster cancer drugs as competition in the immunotherapy space heats up.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news